Trial Profile
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 300mg as Compared to Adding Montelukast 10mg or Placebo Tablets QD to Fluticasone Propionate/Salmeterol 250/50mcg Diskus BID.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2023
Price :
$35
*
At a glance
- Drugs Fiboflapon (Primary) ; Montelukast; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors GSK
- 21 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
- 21 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Aug 2011 Planned end date changed from 1 Jul 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.